You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Références<br />
74. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease<br />
in a cohort of haemophilic patients. Br J Haematol. 1994 Jul;87(3):555-61.<br />
75. Ragni MV, Na<strong>le</strong>snik MA, Schillo R, Dang Q. Highly active antiretroviral therapy improves ESLD-free<br />
survival in HIV-HCV co-infection. Haemophilia. 2009 Mar;15(2):552-8.<br />
76. Engels EA, Frisch M, Lubin JH, Gail MH, Biggar RJ, Goedert JJ. Preva<strong>le</strong>nce of hepatitis C virus infection<br />
and risk for hepatocellular carcinoma and non-Hodgkin lymphoma in AIDS. J Acquir Immune Defic Syndr.<br />
2002 Dec 15;31(5):536-41.<br />
77. Garcia-Samaniego J, Rodriguez M, Berenguer J, Rodriguez-Rosado R, Carbo J, Asensi V, et al.<br />
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol. 2001<br />
Jan;96(1):179-83.<br />
78. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, et al. Mortality from liver<br />
cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with<br />
hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet. 1997 Nov 15;350(9089):1425-31.<br />
79. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral<br />
therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003 Nov<br />
22;362(9397):1708-13.<br />
80. Merchante N, Giron-Gonza<strong>le</strong>z JA, Gonza<strong>le</strong>z-Serrano M, Torre-Cisneros J, Garcia-Garcia JA, Arizcorreta A,<br />
et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. Aids.<br />
2006 Jan 2;20(1):49-57.<br />
81. Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality<br />
increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with<br />
hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):221-5.<br />
82. Zylberberg H, Pialoux G, Carnot F, Landau A, Brechot C, Pol S. Rapidly evolving hepatitis C virus-related<br />
cirrhosis in a human immunodeficiency virus-infected patient receiving trip<strong>le</strong> antiretroviral therapy. Clin<br />
Infect Dis. 1998 Nov;27(5):1255-8.<br />
83. Mehta SH, Thomas DL, Torbenson M, Brink<strong>le</strong>y S, Mirel L, Chaisson RE, et al. The effect of antiretroviral<br />
therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology. 2005 Jan;41(1):123-<br />
31.<br />
84. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected<br />
individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. Aids.<br />
2008 Oct 1;22(15):1979-91.<br />
85. Macias J, Berenguer J, Japon MA, Giron JA, Rivero A, Lopez-Cortes LF, et al. Fast fibrosis progression<br />
between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.<br />
Hepatology. 2009 Jun 19.<br />
86. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Factors affecting liver fibrosis<br />
in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor<br />
therapy. Hepatology. 2001 Aug;34(2):283-7.<br />
87. Marine-Barjoan E, Saint-Paul MC, Pradier C, Chaillou S, Anty R, Michiels JF, et al. Impact of antiretroviral<br />
treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. Aids. 2004 Nov<br />
5;18(16):2163-70.<br />
88. Macias J, Mira JA, Lopez-Cortes LF, Santos I, Giron-Gonza<strong>le</strong>z JA, Gonza<strong>le</strong>z-Serrano M, et al. Antiretroviral<br />
therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with<br />
chronic hepatitis C. Antivir Ther. 2006;11(7):839-46.<br />
89. Verma S, Wang CH, Govindarajan S, Kanel G, Squires K, Bonacini M. Do type and duration of antiretroviral<br />
therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients Clin Infect Dis. 2006 Jan<br />
15;42(2):262-70.<br />
90. Macias J, Castellano V, Merchante N, Palacios RB, Mira JA, Saez C, et al. Effect of antiretroviral drugs on<br />
liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. Aids. 2004 Mar<br />
26;18(5):767-74.<br />
91. Pol S, Lebray P, Val<strong>le</strong>t-Pichard A. HIV infection and hepatic enzyme abnormalities: intricacies of the<br />
pathogenic mechanisms. Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S65-72.<br />
92. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, et al. The influence of human<br />
immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective<br />
cohort study. Hepatology. 2001 Dec;34(6):1193-9.<br />
93. Matthews-Greer JM, Caldito GC, Ad<strong>le</strong>y SD, Willis R, Mire AC, Jamison RM, et al. Comparison of hepatitis<br />
C viral loads in patients with or without human immunodeficiency virus. Clin Diagn Lab Immunol. 2001<br />
Jul;8(4):690-4.<br />
94. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA <strong>le</strong>vels in<br />
hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter<br />
Hemophilia Cohort Study. Blood. 1994 Aug 15;84(4):1020-3.<br />
95. Giovannini M, Tagger A, Ribero ML, Zuccotti G, Pogliani L, Grossi A, et al. Maternal-infant transmission of<br />
hepatitis C virus and HIV infections: a possib<strong>le</strong> interaction. Lancet. 1990 May 12;335(8698):1166.<br />
180
Change language